Published Date: 30 Oct 2023
The INTERLACE phase III trial, run by UCL and UCLH researchers and funded by Cancer Research UK, has made a ground-breaking discovery.
Read Full NewsThe pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.
Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.
Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO
1.
Breast cancer patients' arms swell less after an effective lymph node transfer.
2.
A new device enhances liquid biopsy.
3.
Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.
4.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
5.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
1.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
2.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
3.
HKDC1 Protein: An Emerging Therapeutic Target in Colon Cancer
4.
Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection
5.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation